CD70-CD27通路在肿瘤发生及治疗中作用的研究进展  

Research progress in CD70-CD27 pathway in tumorigenesis and treatment

作　　者：王雷雷 孔英君[1] WANG Leilei;KONG Yingjun(Department of Respiratory Medicine,First Affiliated Hospital,Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院呼吸内科

出　　处：《临床与病理杂志》2019年第9期2021-2025,共5页Journal of Clinical and Pathological Research

摘　　要：随着免疫学的发展,肿瘤的免疫疗法受到了人们的关注,其中CD70是一个新发现的靶点。正常组织中CD70是一种II型跨膜糖蛋白,仅仅短暂地表达在活化的T细胞、B细胞及成熟的树突状细胞(dendritic cells,DC)中。CD27是CD70的受体,需与其结合发挥作用。在病理状态下,CD70可高表达于多种肿瘤细胞中,目前以CD70为靶点的免疫治疗药物已经在临床前期研究中应用。CD70在肿瘤细胞上的表达,不仅可以诱导免疫逃逸,同时也可以激活部分免疫细胞杀伤肿瘤细胞,这给肿瘤的免疫治疗带来了新的方向。With the progress of immunology, tumor immunotherapy has become a hot research topic, in which CD70 is a newly discovered target. In normal tissues, CD70 is a type II transmembrane glycoprotein that is expressed only briefly in activated T cells, B cells and mature dendritic cells (DC). CD27 is the receptor of CD70, which needs to be combined to play a role. It has been confirmed that CD70 can be highly expressed in a variety of tumors. Immunotherapeutic drugs targeting CD70 have been used in preclinical studies. The expression of CD70 in tumor cells can not only induce immune escape, but also activate some immune cells to kill tumor cells, which brings a new direction for the immunotherapy of tumors.

关 键 词：CD70 肿瘤 免疫逃逸 免疫治疗 

分 类 号：R730.2[医药卫生—肿瘤]